Industry revenues:

• Bioenergy: approx. 30%
• Food and beverages: approx. 25%
• Agriculture and nutrition: approx. 20%
• Household care: approx. 15%
• Other industries: approx. 10%

TOP 3 markets:

• USA: approx. 35%
• Europe: approx. 30%
• Asia-Pacific: approx. 20%

Novozymes A/S generates its revenues mainly from biotechnology, with bioenergy and the food and beverage industry accounting for the largest shares. The USA is the largest market for Novozymes, followed by Europe and the Asia-Pacific region. These markets benefit from strong demand for sustainable and efficient biotechnological solutions.

Production sites of Novozymes A/S:

1. Denmark
2. USA
3. Brazil
4. China
5. India

Novozymes A/S produces its products at several international locations to efficiently meet global demand. The main production sites are located in Denmark, where the company is headquartered. In addition, Novozymes operates significant production facilities in the USA, Brazil, China, and India. This geographical diversification enables the company to optimize its supply chains and flexibly respond to regional market requirements.

Revenue Growth: Estimated 5-7% annually (2025) R&D Investments: Over 13% of revenue (2024)

Novozymes A/S pursues a growth strategy that is strongly focused on innovation and sustainability. The company continuously invests a significant portion of its revenue in research and development to develop new and improved biotechnological solutions. These investments aim to expand the product pipeline and access new markets.

Another key focus of the strategy is to strengthen global presence, especially in emerging markets where the demand for sustainable solutions is growing. Novozymes also relies on strategic partnerships and alliances to solidify its market position and gain access to new technologies and markets.

Additionally, the company places great emphasis on sustainability and environmental responsibility, which affects not only product development but the entire value chain. This aligns with the increasing global trend towards environmentally friendly and sustainable business practices, which could give Novozymes a competitive advantage.

Main raw materials: Enzymes, microorganisms, biopolymers

Key importing countries: USA, China, Brazil

Novozymes A/S is a leading company in biotechnology specializing in the production of enzymes and microorganisms. The main raw materials that the company imports include enzymes, microorganisms, and biopolymers needed for the manufacturing of their products.

The USA is one of the most significant suppliers of biotechnological raw materials, especially enzymes and microorganisms. China and Brazil are also important partners, particularly for specific types of enzymes and biotechnological raw materials that play a role in Novozymes' production.

These countries offer a combination of advanced biotechnological infrastructure and cost-effective production capabilities, making them ideal partners for Novozymes.

Market Share: Approx. 48% in the industrial enzymes sector (2024)

Research & Development: 13% of revenue invested (2024)

Patents: Over 7,000 active patents worldwide (2024)

Novozymes A/S possesses a significant competitive advantage, primarily based on its leading position in the industrial enzymes sector. With a market share of around 48%, the company dominates this sector and benefits from high barriers to entry for new competitors.

Another essential factor is the strong focus on research and development. Novozymes invests approximately 13% of its revenue in this area, ensuring continuous innovation and improvement of its products. These investments help the company introduce new and improved enzyme products to the market that meet the changing needs of customers.

Furthermore, Novozymes has an extensive portfolio of over 7,000 active patents worldwide. These patents protect the company's intellectual property and secure its technological advancements, further enhancing its competitive advantage.

Overall, Novozymes' competitive advantage is based on its strong market position, continuous innovation, and robust patent portfolio. This enables the company to successfully compete in a highly competitive environment.

Institutional investor share: approx. 60% (estimated, based on previous trends)

Insider purchases/sales: No significant transactions in the last year (estimated)

The institutional investor share at Novozymes A/S traditionally stands at around 60%, indicating the trust of large investors in the company's long-term strategy and stability. However, this figure may slightly change depending on market conditions and company performance.

Regarding insider transactions, there were no significant purchases or sales in the last year, suggesting that the management and other insiders do not currently anticipate significant changes in the company's valuation. Such transactions are often seen as indicators of executives' confidence in the company's future development.

Market share of Novozymes A/S: 48% (2025, estimated)

Main competitors and their market shares:

1. Novozymes A/S: 48%
2. DuPont (Danisco): 20%
3. DSM: 12%
4. BASF: 8%
5. Chr. Hansen: 6%
6. AB Enzymes: 3%
7. Kerry Group: 2%
8. Advanced Enzyme Technologies: 1%

Novozymes A/S is the leading provider in the industrial enzymes sector and holds a significant market share of 48%. The main competitor, DuPont (Danisco), follows with a market share of 20%. The other competitors have significantly lower shares, which secures Novozymes a strong market position.

The moat of Novozymes is characterized by several factors: a broad product range, strong R&D investments, and long-standing customer relationships. These factors contribute to a high barrier to entry for new competitors and strengthen Novozymes' market position.

Compared to its competitors, Novozymes has a significant advantage due to its innovation capabilities and the ability to offer tailored solutions for various industries. While companies like DuPont also have strong R&D capacities, Novozymes, with its specialization in enzymes, has a deeper moat in this specific market segment.

Revenue growth: 5.8% (2024) EBITDA margin: 28.4% (2024) Research & Development (R&D) expenses: 13% of revenue (2024)

Novozymes A/S is a leading company in the field of biotechnology, specializing in the development of enzymes and microorganisms. In 2024, the company experienced a revenue growth of 5.8%, attributed to a strong demand for sustainable solutions across various industries.

The EBITDA margin of 28.4% indicates Novozymes' ability to efficiently manage its costs and achieve high profitability. This is a positive signal for investors seeking stable and profitable companies.

Another important aspect is the significant investment in research and development, accounting for 13% of revenue. These investments secure the company's innovation capabilities and its ability to develop new products that meet changing market demands.

In summary, Novozymes A/S is an attractive investment opportunity due to its stable financial performance, strong market position, and continuous investments in research and development. However, investors should also consider general market conditions and potential risks in the biotechnology sector.

Dividend yield: 1.8% (2024) Dividend growth: 5% (annually, average over the last 5 years)

Novozymes A/S has consistently paid dividends in recent years, indicating a reliable dividend policy. The dividend yield was recently at 1.8%, which can be considered moderate compared to other companies in the industry.

Over the past five years, the company has recorded an average dividend growth of 5% per year. This stable growth rate suggests that Novozymes is committed to providing its shareholders with regularly increasing payouts. The financial health and strong market position of Novozymes support the sustainability of this dividend policy.